Clinical Trial Update: MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED) [Phase 2]

View source ↗

Summary

The Phase 2 clinical trial MK0952 in mild-to-moderate Alzheimer's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• MK0952

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED